Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01288521 |
|
Recruitment Status :
Completed
First Posted : February 2, 2011
Results First Posted : March 9, 2018
Last Update Posted : March 9, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Solid organ transplant recipients would greatly benefit from pharmacogenetic evaluation since immunosuppressive drug regimens consist of multiple medications with narrow therapeutic ranges and toxic adverse event profiles. Tacrolimus is a potent immunosuppressive agent utilized for rejection prophylaxis. Intensive pharmacokinetic monitoring must be performed following organ transplantation to ensure therapeutic drug concentrations due to its highly variable pharmacokinetics profile and narrow therapeutic index. Tacrolimus is a substrate for CYP450 3A and for the membrane transporter p-glycoprotein (Pgp). Polymorphisms in the gene encoding for CYP3A5 have been extensively studied and have been found to influence the dosing of tacrolimus. The effect of ABCB1 gene polymorphisms (which encodes for Pgp) upon tacrolimus pharmacokinetics has been more difficult to establish.
This study will determine if haplotypes derived from three frequent polymorphisms in the ABCB1 gene (C1236T, G2677T, C3435T) can predict the degree of drug interaction between tacrolimus (CYP3A5/Pgp substrate) and ketoconazole (CYP3A5/Pgp inhibitor) in patients who are CYP3A5 nonexpressors.
This prospective pharmacokinetic and pharmacogenomic study will enroll 20 stable renal transplant recipients with the CYP3A5 *3/*3 genotype and grouped by ABCB1 haplotype (CGC vs TTT). Pharmacokinetics of tacrolimus will be assessed on 2 occasions with and without ketoconazole coadministration separated by 1 week. The order of study occasions will be randomized in a crossover design.
The results of this study may identify a genomic marker for predicting drug-drug interactions. Knowing this information a priori will aid clinicians in modifying drug dosing and alleviate patients of the burden of significant drug toxicities.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Kidney Transplantation | Drug: Tacrolimus + Ketoconazole, Then Tacrolimus alone Drug: Tacrolimus alone, Then Tacrolimus + Ketoconazole | Phase 4 |
Two mL of blood will be obtained for pharmacogenomic screening for CYP3A5 and ABCB1 genotypes. Patients with the CYP3A5*3/*3 genotype will be consented for the pharmacokinetic portion of the study. Volunteers from this patient cohort will participate in 2 overnight visits to the General Clinical Research Center (GCRC).
Patients will report to the GCRC on the evening before each study visit. They will be required to fast from midnight the night before until 1 hour after tacrolimus administration, which will be in the morning approximately at 8 am.
Pharmacokinetics of tacrolimus will be assessed on 2 occasions with and without ketoconazole coadministration separated by 1 week. The order of study occasions will be randomized in a crossover design. Each patient will take their take their usual oral dose of tacrolimus and have whole blood levels obtained immediately before (C0) and at 0.5, 1, 1.5, 2, 3, 4, 6 hours after the tacrolimus dose. They will then receive tacrolimus by intravenous infusion, a therapeutic dose over four hours. The IV dose will take the place of the patients' usual evening dose of tacrolimus. Additional blood will be drawn for tacrolimus at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours after the intravenous dose. During the ketoconazole visit, tacrolimus doses will be decreased by one-half to account for the drug interaction and avoid potential tacrolimus-induced toxicities. Ketoconazole 200 mg will be administered orally every 12 hours for a total of 3 doses; the first ketoconazole dose will be given 13 hours before tacrolimus administration.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 8 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | Utilizing Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients |
| Study Start Date : | October 2008 |
| Actual Primary Completion Date : | June 2011 |
| Actual Study Completion Date : | September 2011 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Tacrolimus + Ketoconazole, Then Tacrolimus alone
Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
|
Drug: Tacrolimus + Ketoconazole, Then Tacrolimus alone
Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
Other Names:
|
|
Experimental: Tacrolimus alone, Then Tacrolimus + Ketoconazole
The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
|
Drug: Tacrolimus alone, Then Tacrolimus + Ketoconazole
Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
Other Names:
|
- Tacrolimus Bioavailability (F) [ Time Frame: baseline and 2 weeks ]Tac bioavailability alone vs. Tac bioavailability with Keto. To determine F we took the ratio of area under the curve of the oral dose divided by the area under the curve of the IV dose. F was determined by fitting a model that considered the plasma concentration of tac with IV vs. oral dosing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Kidney transplant recipient
- > 6 months posttransplant
- Serum creatinine < 1.6 mg/dL
- Currently taking a stable dose of tacrolims
Exclusion Criteria:
- On medications known to interact with tacrolimus or ketoconazole
- Multi-organ transplant recipient
- Serum creatinine >1.5 mg/dL
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01288521
| United States, Iowa | |
| University of Iowa Hospitals and Clinics | |
| Iowa City, Iowa, United States, 52242 | |
| Principal Investigator: | Sony Tuteja, PharmD | University of Iowa |
| Responsible Party: | Sony Tuteja, Associate, University of Iowa |
| ClinicalTrials.gov Identifier: | NCT01288521 History of Changes |
| Other Study ID Numbers: |
200806718 |
| First Posted: | February 2, 2011 Key Record Dates |
| Results First Posted: | March 9, 2018 |
| Last Update Posted: | March 9, 2018 |
| Last Verified: | February 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Keywords provided by Sony Tuteja, University of Iowa:
|
kidney transplantation tacrolimus P-glycoprotein ABCB1 genotyping |
Additional relevant MeSH terms:
|
Tacrolimus Ketoconazole Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Antifungal Agents Anti-Infective Agents 14-alpha Demethylase Inhibitors Cytochrome P-450 Enzyme Inhibitors Steroid Synthesis Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Cytochrome P-450 CYP3A Inhibitors |